GCA
NBIX icon

Gideon Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Gideon Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,230
Closed -$562K – 139
2019
Q4 		$562K Buy
+5,230
New +$548K 0.19% 161
2018
Q4 		– Sell
-1,725
Closed -$212K – 461
2018
Q3 		$212K Sell
1,725
-1,591
-48% -$181K 0.1% 309
2018
Q2 		$326K Buy
+3,316
New +$297K 0.16% 237

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Gideon Capital Advisors's NBIX Position: Q1 2020 in Review

Gideon Capital Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2020, closing a stake of 5,230 shares — an estimated $562K sold.

Gideon Capital Advisors first reported a position in NBIX in Q2 2018 and held it in 3 quarters. The position peaked at $562K in Q4 2019. 369 funds tracked by Wall St. Rank hold NBIX as of Q1 2020.

  • Gideon Capital Advisors reported no remaining Neurocrine Biosciences position as of Q1 2020 after selling out during the quarter.
  • Gideon Capital Advisors sold 5,230 Neurocrine Biosciences shares in Q1 2020, an estimated $562K.
  • Gideon Capital Advisors first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 3 quarters.
  • Gideon Capital Advisors's Neurocrine Biosciences position peaked at $562K in Q4 2019.
  • 369 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2020.

Based on Gideon Capital Advisors's 13F filing for Q1 2020.